Kanabo Group
Offers a medical-grade, unified ecosystem for accurate consumption of cannabis formulas.
| GBP | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 726 % | 48 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (1407 %) | (704 %) | (191 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (6234 %) | (1139 %) | (892 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 353 % | 99 % | 43 % |
Source: Company filings or news article
Related Content
Kanabo Group, based in The Weizmann Science Park in Israel, is a pioneering company in the cannabis industry. The company focuses on developing medical-grade cannabis formulas and innovative vaporization devices aimed at improving health and well-being. Kanabo serves patients with Central Nervous System (CNS) disorders and those seeking better sleep solutions. Operating in the medical cannabis market, Kanabo's business model is holistic, encompassing research, cultivation, and consumption. This integrated approach ensures high-quality and precise products. Revenue is generated through the sale of cannabis formulations and the VapePod device, which has undergone medical validation studies. The company's mission is to unlock the full potential of cannabis to enhance life quality.
Keywords: medical-grade, cannabis, vaporization, CNS disorders, sleep solutions, holistic model, research, cultivation, consumption, VapePod.
Investments by Kanabo Group
Edit
